Lupin, Celon announce strategic agreement

Pharma major Lupin and Polish biopharmaceutical company Celon announced that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product.


(Photo Courtesy:

This dry powder is the generic version of GlaxoSmithKline's (GSK) Advair Diskus.

Lupin will be responsible for commercialization of the product.

Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico, and other key markets.

Commenting on the development, Lupin's CEO Ms Vinita Gupta voiced, "This collaboration is an important milestone in Lupin's efforts to evolve its global inhalation pipeline. We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe. This coupled with Lupin's expertise in inhalation product development and commercialization in the US and other markets will accelerate the development of generic Advair Diskus for global markets. We look forward to providing access to high quality, affordable fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets."

GSK's Advair Diskus had global sales of over $7 billion as of last fiscal.

Celon's CMD Dr Maciej Wieczorek opined, "Our scientific and technical teams look forward to collaborating with Lupin to bring this product to major markets outside of Poland. We are enthusiastic and believe that both the companies would work together to complete a time bound R&D program to ensure successful registration in targeted markets, for Lupin to effectively commercialize the product."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email